SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
-8.63%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$604M
AUM Growth
+$604M
(-20%)
Cap. Flow
-$57.3M
Cap. Flow
% of AUM
-9.5%
Top 10 Holdings %
Top 10 Hldgs %
56.78%
Holding
110
New
23
Increased
21
Reduced
26
Closed
29
Top Buys
| 1 |
AstraZeneca
AZN
|
$25.5M |
| 2 |
Merck
MRK
|
$24.1M |
| 3 |
Pfizer
PFE
|
$18M |
| 4 |
AbbVie
ABBV
|
$12.6M |
| 5 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$12M |
Top Sells
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$21.3M |
| 2 |
Verint Systems
VRNT
|
$16.1M |
| 3 |
Johnson & Johnson
JNJ
|
$11.8M |
| 4 |
Viatris
VTRS
|
$11.3M |
| 5 |
PTC Therapeutics
PTCT
|
$10.3M |
Sector Composition
| 1 | Healthcare | 87.4% |
| 2 | Technology | 6% |
| 3 | Consumer Discretionary | 1.7% |
| 4 | Communication Services | 0.44% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
26
DELISTED
Blueprint Medicines
BPMC
| $6.4M | 0.8% | 109,500 +3,500 | +3% | +$205K |
|
27
Arvinas
ARVN
$568M
| $5.88M | 0.73% | 145,781 -53,000 | -27% | -$2.14M |
|
28
ADMA Biologics
ADMA
$4.12B
| $5.29M | 0.66% | 1,838,100 +1,298,100 | +240% | +$3.74M |
|
29
Salesforce
CRM
$245B
| $5.12M | 0.64% | +35,529 | New | +$5.12M |
|
|
TRIL
30
DELISTED
Trillium Therapeutics Inc.
TRIL
| $5.09M | 0.64% | +1,260,694 | New | +$5.09M |
|
31
AudioCodes
AUDC
$273M
| $4.94M | 0.62% | 206,619 -99,434 | -32% | -$2.38M |
|
|
DCPH
32
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $4.92M | 0.62% | +119,500 | New | +$4.92M |
|
33
Exicure
XCUR
$35.4M
| $4.86M | 0.61% | 3,284,795 +395,907 | +14% | +$586K |
|
34
Beam Therapeutics
BEAM
$1.66B
| $4.76M | 0.6% | +264,681 | New | +$4.76M |
|
35
Rocket Pharmaceuticals
RCKT
$354M
| $4.67M | 0.58% | 335,016 -26,872 | -7% | -$375K |
|
|
GRTX
36
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $4.52M | 0.57% | 475,677 +4,238 | +0.9% | +$40.3K |
|
37
Neurogene
NGNE
$264M
| $4.52M | 0.57% | 397,000 +17,002 | +4% | +$193K |
|
|
ORGS
38
DELISTED
Orgenesis Inc. Common Stock
ORGS
| $4.22M | 0.53% | +1,109,564 | New | +$4.22M |
|
39
Protagonist Therapeutics
PTGX
$3.67B
| $3.71M | 0.46% | 526,075 -103,925 | -16% | -$734K |
|
40
Ascendis Pharma
ASND
$11.8B
| $3.67M | 0.46% | 32,573 -41,200 | -56% | -$4.64M |
|
41
Teva Pharmaceuticals
TEVA
$21.1B
| $3.2M | 0.4% | 356,713 +96,361 | +37% | +$865K |
|
|
KA
42
DELISTED
Kineta, Inc. Common Stock
KA
| $2.89M | 0.36% | 2,536,600 | – | – |
|
43
Viking Therapeutics
VKTX
$3.04B
| $2.76M | 0.35% | 590,000 | – | – |
|
44
Palo Alto Networks
PANW
$127B
| $2.7M | 0.34% | 16,452 -14,524 | -47% | -$2.38M |
|
45
Aldeyra Therapeutics
ALDX
$351M
| $2.64M | 0.33% | 1,069,089 | – | – |
|
46
Fiverr
FVRR
$870M
| $2.64M | 0.33% | 104,839 -128,966 | -55% | -$3.25M |
|
47
Cassava Sciences
SAVA
$110M
| $2.53M | 0.32% | +615,000 | New | +$2.53M |
|
48
Larimar Therapeutics
LRMR
$310M
| $2.43M | 0.3% | 3,161,562 +2,813,892 | +809% | +$2.17M |
|
49
Evolus
EOLS
$494M
| $2.28M | 0.29% | 550,000 +400,000 | +267% | +$1.66M |
|
|
ARYAU
50
DELISTED
ARYA Sciences Acquisiton Corp. Unit
ARYAU
| $2.26M | 0.28% | 200,000 | – | – |
|